Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Shares of Apple and Dell Technologies rise sharply after the Trump administration exempts smartphones, computers, memory ...

The performance gap between high- and low-liquidity stocks has remained surprisingly stable despite recent market turbulence ...

We recently published a list of 15 Best Large-Cap Value Stocks to Buy as the Recession Hits. In this article, we are going to ...

Fintel reports that on April 8, 2025, Goldman Sachs downgraded their outlook for Pfizer (SNSE:PFECL) from Buy to Neutral. There are 4,005 funds or institutions reporting positions in Pfizer.

Eli Lilly (LLY) stock and Johnson & Johnson (JNJ) stock are upgraded and Pfizer (PFE) stock and AbbVie (ABBV) stock downgraded at Goldman Sachs. Read more here.

Goldman Sachs initiated coverage on several large-cap pharmaceutical companies, taking a cautious stance on Bristol-Myers Squibb (NYSE:BMY), Pfizer (NYSE:PFE), and AbbVie (NYSE:ABBV), while upgrading ...

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

Fintel reports that on April 8, 2025, Goldman Sachs downgraded their outlook for Pfizer (BIT:1PFE) from Buy to Neutral. As of April 4, 2025, the average one-year price target for Pfizer is €28. ...

Goldman Sachs downgraded Pfizer (PFE) to Neutral from Buy with a price target of $25, down from $32, after assuming coverage of the name. The ...